Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.
Identifieur interne : 000572 ( PubMed/Checkpoint ); précédent : 000571; suivant : 000573Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.
Auteurs : Jared S. Morse [États-Unis] ; Tyler Lalonde [États-Unis] ; Shiqing Xu [États-Unis] ; Wenshe Ray Liu [États-Unis]Source :
- Chembiochem : a European journal of chemical biology [ 1439-7633 ] ; 2020.
Descripteurs français
- KwdFr :
- Antiviraux (), Antiviraux (usage thérapeutique), Conception de médicament, Cysteine endopeptidases (), Cysteine endopeptidases (génétique), Cysteine endopeptidases (métabolisme), Humains, Infections à coronavirus (), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (transmission), Pneumopathie virale (), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (transmission), RNA replicase (), RNA replicase (génétique), RNA replicase (métabolisme).
- MESH :
- génétique : Cysteine endopeptidases, RNA replicase.
- métabolisme : Cysteine endopeptidases, RNA replicase.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antiviraux, Infections à coronavirus, Pneumopathie virale.
- Antiviraux, Conception de médicament, Cysteine endopeptidases, Humains, Infections à coronavirus, Pneumopathie virale, RNA replicase.
English descriptors
- KwdEn :
- Antiviral Agents (chemistry), Antiviral Agents (therapeutic use), Betacoronavirus (enzymology), Betacoronavirus (genetics), Coronavirus Infections (drug therapy), Coronavirus Infections (prevention & control), Coronavirus Infections (transmission), Cysteine Endopeptidases (chemistry), Cysteine Endopeptidases (genetics), Cysteine Endopeptidases (metabolism), Drug Design, Humans, Pneumonia, Viral (drug therapy), Pneumonia, Viral (prevention & control), Pneumonia, Viral (transmission), RNA Replicase (chemistry), RNA Replicase (genetics), RNA Replicase (metabolism).
- MESH :
- chemical , chemistry : Antiviral Agents, Cysteine Endopeptidases, RNA Replicase.
- chemical , genetics : Cysteine Endopeptidases, RNA Replicase.
- chemical , metabolism : Cysteine Endopeptidases, RNA Replicase.
- chemical , therapeutic use : Antiviral Agents.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- enzymology : Betacoronavirus.
- genetics : Betacoronavirus.
- prevention & control : Coronavirus Infections, Pneumonia, Viral.
- transmission : Coronavirus Infections, Pneumonia, Viral.
- Drug Design, Humans.
Abstract
With the current trajectory of the 2019-nCoV outbreak unknown, public health and medicinal measures will both be needed to contain spreading of the virus and to optimize patient outcomes. Although little is known about the virus, an examination of the genome sequence shows strong homology with its better-studied cousin, SARS-CoV. The spike protein used for host cell infection shows key nonsynonymous mutations that might hamper the efficacy of previously developed therapeutics but remains a viable target for the development of biologics and macrocyclic peptides. Other key drug targets, including RNA-dependent RNA polymerase and coronavirus main proteinase (3CLpro), share a strikingly high (>95 %) homology to SARS-CoV. Herein, we suggest four potential drug candidates (an ACE2-based peptide, remdesivir, 3CLpro-1 and a novel vinylsulfone protease inhibitor) that could be used to treat patients suffering with the 2019-nCoV. We also summarize previous efforts into drugging these targets and hope to help in the development of broad-spectrum anti-coronaviral agents for future epidemics.
DOI: 10.1002/cbic.202000047
PubMed: 32022370
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32022370Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.</title><author><name sortKey="Morse, Jared S" sort="Morse, Jared S" uniqKey="Morse J" first="Jared S" last="Morse">Jared S. Morse</name><affiliation wicri:level="1"><nlm:affiliation>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843</wicri:regionArea><wicri:noRegion>77843</wicri:noRegion></affiliation></author><author><name sortKey="Lalonde, Tyler" sort="Lalonde, Tyler" uniqKey="Lalonde T" first="Tyler" last="Lalonde">Tyler Lalonde</name><affiliation wicri:level="1"><nlm:affiliation>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843</wicri:regionArea><wicri:noRegion>77843</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Shiqing" sort="Xu, Shiqing" uniqKey="Xu S" first="Shiqing" last="Xu">Shiqing Xu</name><affiliation wicri:level="1"><nlm:affiliation>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843</wicri:regionArea><wicri:noRegion>77843</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Wenshe Ray" sort="Liu, Wenshe Ray" uniqKey="Liu W" first="Wenshe Ray" last="Liu">Wenshe Ray Liu</name><affiliation wicri:level="1"><nlm:affiliation>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843</wicri:regionArea><wicri:noRegion>77843</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32022370</idno><idno type="pmid">32022370</idno><idno type="doi">10.1002/cbic.202000047</idno><idno type="wicri:Area/PubMed/Corpus">000B94</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B94</idno><idno type="wicri:Area/PubMed/Curation">000B94</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B94</idno><idno type="wicri:Area/PubMed/Checkpoint">000572</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000572</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.</title><author><name sortKey="Morse, Jared S" sort="Morse, Jared S" uniqKey="Morse J" first="Jared S" last="Morse">Jared S. Morse</name><affiliation wicri:level="1"><nlm:affiliation>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843</wicri:regionArea><wicri:noRegion>77843</wicri:noRegion></affiliation></author><author><name sortKey="Lalonde, Tyler" sort="Lalonde, Tyler" uniqKey="Lalonde T" first="Tyler" last="Lalonde">Tyler Lalonde</name><affiliation wicri:level="1"><nlm:affiliation>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843</wicri:regionArea><wicri:noRegion>77843</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Shiqing" sort="Xu, Shiqing" uniqKey="Xu S" first="Shiqing" last="Xu">Shiqing Xu</name><affiliation wicri:level="1"><nlm:affiliation>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843</wicri:regionArea><wicri:noRegion>77843</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Wenshe Ray" sort="Liu, Wenshe Ray" uniqKey="Liu W" first="Wenshe Ray" last="Liu">Wenshe Ray Liu</name><affiliation wicri:level="1"><nlm:affiliation>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843</wicri:regionArea><wicri:noRegion>77843</wicri:noRegion></affiliation></author></analytic><series><title level="j">Chembiochem : a European journal of chemical biology</title><idno type="eISSN">1439-7633</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (chemistry)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (enzymology)</term><term>Betacoronavirus (genetics)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (prevention & control)</term><term>Coronavirus Infections (transmission)</term><term>Cysteine Endopeptidases (chemistry)</term><term>Cysteine Endopeptidases (genetics)</term><term>Cysteine Endopeptidases (metabolism)</term><term>Drug Design</term><term>Humans</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (prevention & control)</term><term>Pneumonia, Viral (transmission)</term><term>RNA Replicase (chemistry)</term><term>RNA Replicase (genetics)</term><term>RNA Replicase (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux ()</term><term>Antiviraux (usage thérapeutique)</term><term>Conception de médicament</term><term>Cysteine endopeptidases ()</term><term>Cysteine endopeptidases (génétique)</term><term>Cysteine endopeptidases (métabolisme)</term><term>Humains</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (transmission)</term><term>Pneumopathie virale ()</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (transmission)</term><term>RNA replicase ()</term><term>RNA replicase (génétique)</term><term>RNA replicase (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term><term>Cysteine Endopeptidases</term><term>RNA Replicase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Cysteine Endopeptidases</term><term>RNA Replicase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cysteine Endopeptidases</term><term>RNA Replicase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Cysteine endopeptidases</term><term>RNA replicase</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cysteine endopeptidases</term><term>RNA replicase</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Design</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Antiviraux</term><term>Conception de médicament</term><term>Cysteine endopeptidases</term><term>Humains</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>RNA replicase</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">With the current trajectory of the 2019-nCoV outbreak unknown, public health and medicinal measures will both be needed to contain spreading of the virus and to optimize patient outcomes. Although little is known about the virus, an examination of the genome sequence shows strong homology with its better-studied cousin, SARS-CoV. The spike protein used for host cell infection shows key nonsynonymous mutations that might hamper the efficacy of previously developed therapeutics but remains a viable target for the development of biologics and macrocyclic peptides. Other key drug targets, including RNA-dependent RNA polymerase and coronavirus main proteinase (3CLpro), share a strikingly high (>95 %) homology to SARS-CoV. Herein, we suggest four potential drug candidates (an ACE2-based peptide, remdesivir, 3CLpro-1 and a novel vinylsulfone protease inhibitor) that could be used to treat patients suffering with the 2019-nCoV. We also summarize previous efforts into drugging these targets and hope to help in the development of broad-spectrum anti-coronaviral agents for future epidemics.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32022370</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-7633</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>03</Month><Day>02</Day></PubDate></JournalIssue><Title>Chembiochem : a European journal of chemical biology</Title><ISOAbbreviation>Chembiochem</ISOAbbreviation></Journal><ArticleTitle>Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.</ArticleTitle><Pagination><MedlinePgn>730-738</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cbic.202000047</ELocationID><Abstract><AbstractText>With the current trajectory of the 2019-nCoV outbreak unknown, public health and medicinal measures will both be needed to contain spreading of the virus and to optimize patient outcomes. Although little is known about the virus, an examination of the genome sequence shows strong homology with its better-studied cousin, SARS-CoV. The spike protein used for host cell infection shows key nonsynonymous mutations that might hamper the efficacy of previously developed therapeutics but remains a viable target for the development of biologics and macrocyclic peptides. Other key drug targets, including RNA-dependent RNA polymerase and coronavirus main proteinase (3CLpro), share a strikingly high (>95 %) homology to SARS-CoV. Herein, we suggest four potential drug candidates (an ACE2-based peptide, remdesivir, 3CLpro-1 and a novel vinylsulfone protease inhibitor) that could be used to treat patients suffering with the 2019-nCoV. We also summarize previous efforts into drugging these targets and hope to help in the development of broad-spectrum anti-coronaviral agents for future epidemics.</AbstractText><CopyrightInformation>© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morse</LastName><ForeName>Jared S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lalonde</LastName><ForeName>Tyler</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Shiqing</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wenshe Ray</ForeName><Initials>WR</Initials><Identifier Source="ORCID">0000-0002-7078-6534</Identifier><AffiliationInfo><Affiliation>The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01GM121584</GrantID><Agency>National Insitute of Health</Agency><Country>International</Country></Grant><Grant><GrantID>R01GM127575</GrantID><Agency>National Insitute of Health</Agency><Country>International</Country></Grant><Grant><GrantID>RP170797</GrantID><Agency>The Cancer Prevention & Research Institute of Texas</Agency><Country>International</Country></Grant><Grant><GrantID>A-1715</GrantID><Agency>Welch Foundation</Agency><Country>International</Country></Grant><Grant><GrantID>R01GM121584</GrantID><Agency>National Insitutes of Health</Agency><Country>International</Country></Grant><Grant><GrantID>R01GM127575</GrantID><Agency>National Insitutes of Health</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Chembiochem</MedlineTA><NlmUniqueID>100937360</NlmUniqueID><ISSNLinking>1439-4227</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber><NameOfSubstance UI="D012324">RNA Replicase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C099456">3C-like proteinase, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012324" MajorTopicYN="N">RNA Replicase</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">2019-nCoV</Keyword><Keyword MajorTopicYN="Y">3CLpro</Keyword><Keyword MajorTopicYN="Y">RdRp</Keyword><Keyword MajorTopicYN="Y">SARS</Keyword><Keyword MajorTopicYN="Y">antiviral agents</Keyword><Keyword MajorTopicYN="Y">coronavirus</Keyword><Keyword MajorTopicYN="Y">spike proteins</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>01</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32022370</ArticleId><ArticleId IdType="doi">10.1002/cbic.202000047</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>P. Zhou, X. L. Yang, X. G. Wang, B. Hu, L. Zhang, W. Zhang, H. R. Si, Y. Zhu, B. Li, C. L. Huang, H. D. Chen, J. Chen, Y. Luo, H. Guo, R. D. Jiang, M. Q. Liu, Y. Chen, X. R. Shen, X. Wang, X. S. Zheng, K. Zhao, Q. J. Chen, F. Deng, L. L. Liu, B. Yan, F. X. Zhan, Y. Y. Wang, G. Xiao, Z. Shi, bioRxiv 2020, https://www.biorxiv.org/content/10.1101/2020.01.22.914952v2 (accessed Jan. 25, 2020).</Citation></Reference><Reference><Citation>F. Li, W. Li, M. Farzan, S. C. Harrison, Science 2005, 309, 1864-1868.</Citation></Reference><Reference><Citation>N. Dong, X. Yang, L. Ye, K. Chen, E. W. C. Chan, M. Yang, S. Chen, bioRxiv 2020, https://www.biorxiv.org/content/10.1101/2020.01.20.913368v2 (accessed Jan. 25, 2020).</Citation></Reference><Reference><Citation>P. V. Baranov, C. M. Henderson, C. B. Anderson, R. F. Gesteland, J. F. Atkins, M. T. Howard, Virology 2005, 332, 498-510.</Citation></Reference><Reference><Citation>J. Ziebuhr, E. J. Snijder, A. E. Gorbalenya, J. Gen. Virol. 2000, 81, 853-879.</Citation></Reference><Reference><Citation>X. Xu, Y. Liu, S. Weiss, E. Arnold, S. G. Sarafianos, J. Ding, Nucleic Acids Res. 2003, 31, 7117-7130.</Citation></Reference><Reference><Citation>C. C. Li, X. J. Wang, H. C. R. Wang, Drug Discovery Today 2019, 24, 726-736.</Citation></Reference><Reference><Citation>D. Cavanagh, Avian Pathol. 2003, 32, 567-582.</Citation></Reference><Reference><Citation>L. Du, Y. He, Y. Zhou, S. Liu, B. J. Zheng, S. Jiang, Nat. Rev. Microbiol. 2009, 7, 226-236.</Citation></Reference><Reference><Citation>S. Jiang, Y. He, S. Liu, Emerging Infect. Dis. 2005, 11, 1016-1020.</Citation></Reference><Reference><Citation>D. R. Taylor, Vaccine 2006, 24, 863-871.</Citation></Reference><Reference><Citation>R. L. Roper, K. E. Rehm, Expert Rev. Vaccines 2009, 8, 887-898.</Citation></Reference><Reference><Citation>K. V. Holmes, J. Clin. Invest. 2003, 111, 1605-1609.</Citation></Reference><Reference><Citation>S. R. Navas-Martin, S. Weiss, J. Neurovirol. 2004, 10, 75-85.</Citation></Reference><Reference><Citation>Y. He, Y. Zhou, S. Liu, Z. Kou, W. Li, M. Farzan, S. Jiang, Biochem. Biophys. Res. Commun. 2004, 324, 773-781.</Citation></Reference><Reference><Citation>K. T. O′Neil, R. H. Hoess, S. A. Jackson, N. S. Ramachandran, S. A. Mousa, W. F. DeGrado, Proteins 1992, 14, 509-515.</Citation></Reference><Reference><Citation>M. A. McLafferty, R. B. Kent, R. C. Ladner, W. Markland, Gene 1993, 128, 29-36.</Citation></Reference><Reference><Citation>C. J. Hipolito, H. Suga, Curr. Opin. Chem. Biol. 2012, 16, 196-203.</Citation></Reference><Reference><Citation>S. Palei, K. S. Becher, C. Nienberg, J. Jose, H. D. Mootz, ChemBioChem 2019, 20, 72-77.</Citation></Reference><Reference><Citation>W. Xiao, Y. Wang, E. Y. Lau, J. Luo, N. Yao, C. Shi, L. Meza, H. Tseng, Y. Maeda, P. Kumaresan, R. Liu, F. C. Lightstone, Y. Takada, K. S. Lam, Mol. Cancer Ther. 2010, 9, 2714-2723.</Citation></Reference><Reference><Citation>X. S. Wang, P. H. C. Chen, J. T. Hampton, J. M. Tharp, C. A. Reed, S. K. Das, D. S. Wang, H. S. Hayatshahi, Y. Shen, J. Liu, W. R. A. Liu, Angew. Chem. Int. Ed. 2019, 58, 15904-15909;</Citation></Reference><Reference><Citation>Angew. Chem. 2019, 131, 16051-16056.</Citation></Reference><Reference><Citation>H. Hu, L. Li, R. Y. Kao, B. Kou, Z. Wang, L. Zhang, H. Zhang, Z. Hao, W. H. Tsui, A. Ni, L. Cui, B. Fan, F. Guo, S. Rao, C. Jiang, Q. Li, M. Sun, W. He, G. Liu, J. Comb. Chem. 2005, 7, 648-656.</Citation></Reference><Reference><Citation>D. P. Han, A. Penn-Nicholson, M. W. Cho, Virology 2006, 350, 15-25.</Citation></Reference><Reference><Citation>R. N. Kirchdoerfer, A. B. Ward, Nat. Commun. 2019, 10, 2342.</Citation></Reference><Reference><Citation>R. G. González, B. J. Blackburn, T. Schleich, Biochim. Biophys. Acta Nucleic Acids Protein Synth. 1979, 562, 534-545.</Citation></Reference><Reference><Citation>M. Cushman, P. Wang, S. H. Chang, C. Wild, E. De Clercq, D. Schols, M. E. Goldman, J. A. Bowen, J. Med. Chem. 1991, 34, 329-337.</Citation></Reference><Reference><Citation>R. He, A. Adonov, M. Traykova-Adonova, J. Cao, T. Cutts, E. Grudesky, Y. Deschambaul, J. Berry, M. Drebot, X. Li, Biochem. Biophys. Res. Commun. 2004, 320, 1199-1203.</Citation></Reference><Reference><Citation>Y. Yap, X. Zhang, A. Andonov, R. He, Comput. Biol. Chem. 2005, 29, 212-219.</Citation></Reference><Reference><Citation>H. E. Chiou, C. L. Liu, M. J. Buttrey, H. P. Kuo, H. W. Liu, H. T. Kuo, Y. T. Lu, Chest 2005, 128, 263-272.</Citation></Reference><Reference><Citation>M. P. Muller, L. Dresser, J. Raboud, A. McGeer, E. Rea, S. E. Richardson, T. Mazzulli, M. Loeb, M. Louie, S. R. N. Canadian, Pharmacotherapy 2007, 27, 494-503.</Citation></Reference><Reference><Citation>J. A. Al-Tawfiq, H. Momattin, J. Dib, Z. A. Memish, J. Infect. Dis. 2014, 20, 42-46.</Citation></Reference><Reference><Citation>E. C. Smith, H. Blanc, M. Vignuzzi, M. R. Denison, PLoS Pathog. 2013, 9, e1003565.</Citation></Reference><Reference><Citation>L. J. Stockman, R. Bellamy, P. Garner, PLoS Med. 2006, 3, e343.</Citation></Reference><Reference><Citation>F. Ferron, L. Subissi, A. T. S. De Morais, N. T. T. Le, M. Sevajol, L. Gluais, E. Decroly, C. Vonrhein, G. Bricogne, B. Canard, I. Imbert, Proc. Natl. Acad. Sci. USA 2018, 115, E162-E171.</Citation></Reference><Reference><Citation>T. P. Sheahan, A. C. Sims, R. L. Graham, V. D. Menachery, L. E. Gralinski, J. B. Case, S. R. Leist, K. Pyrc, J. Y. Feng, I. Trantcheva, R. Bannister, Y. Park, D. Babusis, M. O. Clarke, R. L. Mackman, J. E. Spahn, C. A. Palmiotti, D. Siegel, A. S. Ray, T. Cihlar, R. Jordan, M. R. Denison, R. S. Baric, Sci. Transl. Med. 2017, 9, eaal3653.</Citation></Reference><Reference><Citation>M. L. Agostini, E. L. Andres, A. C. Sims, R. L. Graham, T. P. Sheahan, X. Lu, E. C. Smith, J. B. Case, J. Y. Feng, R. Jordan, A. S. Ray, T. Cihlar, D. Siegel, R. L. Mackman, M. O. Clarke, R. S. Baric, M. R. Denison, mBio 2018, 9, e00221-18.</Citation></Reference><Reference><Citation>Y. M. Báez-Santos, St. S. E. John, A. D. Mesecar, Antiviral Res. 2015, 115, 21-38.</Citation></Reference><Reference><Citation>T. W. Lee, M. M. Cherney, C. Huitema, J. Liu, K. E. James, J. C. Powers, L. D. Eltis, M. N. James, J. Mol. Biol. 2005, 353, 1137-1151.</Citation></Reference><Reference><Citation>K. Ratia, A. Kilianski, Y. M. Baez-Santos, S. C. Baker, A. Mesecar, PLoS Pathog. 2014, 10, e1004113.</Citation></Reference><Reference><Citation>X. Chen, C. Y. Chou, G. G. Chang, Antiviral Chem. Chemother. 2009, 19, 151-156.</Citation></Reference><Reference><Citation>K. W. Cheng, S. C. Cheng, W. Y. Chen, M. H. Lin, S. J. Chuang, I. H. Cheng, C. Y. Sun, C. Y. Chou, Antiviral Res. 2015, 115, 9-16.</Citation></Reference><Reference><Citation>V. Kumar, J. S. Shin, J. J. Shie, K. B. Ku, C. Kim, Y. Y. Go, K. F. Huang, M. Kim, P. H. Liang, Antiviral Res. 2017, 141, 101-106.</Citation></Reference><Reference><Citation>W. Liu, H. M. Zhu, G. J. Niu, E. Z. Shi, J. Chen, B. Sun, W. Q. Chen, H. G. Zhou, C. Yang, Bioorg. Med. Chem. 2014, 22, 292-302.</Citation></Reference><Reference><Citation>J. Y. Park, H. J. Jeong, J. H. Kim, Y. M. Kim, S. J. Park, D. Kim, K. H. Park, W. S. Lee, Y. B. Ryu, Biol. Pharm. Bull. 2012, 35, 2036-2042.</Citation></Reference><Reference><Citation>J. Y. Park, J. A. Ko, D. W. Kim, Y. M. Kim, H. J. Kwon, H. J. Jeong, C. Y. Kim, K. H. Park, W. S. Lee, Y. B. Ryu, J. Enzyme Inhib. Med. Chem. 2016, 31, 23-30.</Citation></Reference><Reference><Citation>Y. Zhou, P. Vedantham, K. Lu, J. Agudelo, R. Carrion, Jr., J. W. Nunneley, D. Barnard, S. Pohlmann, J. H. McKerrow, A. R. Renslo, G. Simmons, Antiviral Res. 2015, 116, 76-84.</Citation></Reference><Reference><Citation>Y. Kim, V. Shivanna, S. Narayanan, A. M. Prior, S. Weerasekara, D. H. Hua, A. C. Kankanamalage, W. C. Groutas, K. O. Chang, J. Virol. 2015, 89, 4942-4950.</Citation></Reference><Reference><Citation>Y. Kim, H. Liu, A. C. Galasiti Kankanamalage, S. Weerasekara, D. H. Hua, W. C. Groutas, K. O. Chang, N. C. Pedersen, PLoS Pathog. 2016, 12, e1005531.</Citation></Reference><Reference><Citation>Y. H. Song, D. W. Kim, M. J. Curtis-Long, H. J. Yuk, Y. Wang, N. Zhuang, K. H. Lee, K. S. Jeon, K. H. Park, Biol. Pharm. Bull. 2014, 37, 1021-1028.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Morse, Jared S" sort="Morse, Jared S" uniqKey="Morse J" first="Jared S" last="Morse">Jared S. Morse</name></noRegion><name sortKey="Lalonde, Tyler" sort="Lalonde, Tyler" uniqKey="Lalonde T" first="Tyler" last="Lalonde">Tyler Lalonde</name><name sortKey="Liu, Wenshe Ray" sort="Liu, Wenshe Ray" uniqKey="Liu W" first="Wenshe Ray" last="Liu">Wenshe Ray Liu</name><name sortKey="Xu, Shiqing" sort="Xu, Shiqing" uniqKey="Xu S" first="Shiqing" last="Xu">Shiqing Xu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000572 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000572 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:32022370
|texte= Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32022370" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |